Clinical Trials Browser

Phase 1/2 × Recruiting × Blastic Plasmacytoid Dendritic Cell Neoplasm × Clear all

NCT06006403 2023-08-30

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

Phase 1/2 Recruiting

MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Leukemia, Myeloid, Acute